Comparison of tobramycin pharmacokinetics after administration by CRIS and a traditional intravenous piggyback infusion

V. F. Mauro, L. R. Jacobs, L. S. Mauro, Rodger David MacArthur, D. B. White

Research output: Contribution to journalArticle

Abstract

OBJECTIVE: To compare the administration pharmacokinetics of a 30-minute intravenous piggyback (ivpb) infusion of tobramycin with those of controlled- release infusion system (CRIS) using a 20-mL vial at rates of 60 and 120 mL/h. DESIGN: Randomized, controlled, crossover, prospective, open-label trial. SETTING: Medical college-affiliated hospital. PARTICIPANTS: Eight healthy volunteer men between the ages of 22 and 24 years weighing between 60 and 90 kg. INTERVENTIONS: Volunteers received, in random order, tobramycin sulfate 2 mg/kg iv on 3 occasions separated by 1 week. The drug was administered using a 50-mL ivpb infusion at 100 mL/h for 30 minutes, and with the CRIS using a 20-mL vial with flow rates of 60 mL/h for 1 hour (slow) and 120 mL/h for 1 hour (fast). MAIN OUTCOME MEASURES: Primary endpoint were area under the time-concentration curve (AUC), time to reach maximum concentration (t(max)), and maximum concentration (C(max)). Secondary endpoints were elimination rate constant (k(e)), clearance (Cl), and half-life (t( 1/2 )). RESULTS: Six volunteers successfully completed the trial. The t(max) values observed following fast CRIS and ivpb were 28 ± 8 and 32 ± 4 minutes, respectively, and not significantly different from each other. Both occurred significantly earlier than the t(max) associated with slow CRIS (44 ± 7 min), The C(max) values observed following ivpb (11.2 ± 1.5 mg/L) and slow CRIS (10.9 ± 0.9 mg/L) administration were not significantly different from each other, but both were significantly lower than that of fast CRIS (13.4 ± 1.5 mg/L). The AUCs of slow and fast CRIS were 29.8 ± 4.8 and 31.2 ± 3.8 mg/L · h, respectively, and were not significantly different from each other. The AUC of first CRIS was significantly greater than that observed with ivpb (27.4 ± 4.3 mg/L · h). No significant difference in k(e) (fast CRIS 0.32 ± 0.03 h -1 ; slow CRIS 0.33 ± 0.04 h -1 ; ivpb 0.34 ± 0.0 h - 1 ) was observed among any of the methods. CONCLUSIONS: CRIS administration of tobramycin resulted in higher AUCs than did ivpb administration. Compared with ivpb, fast CRIS resulted in a higher C(max), but the t(max) values of fast CRIS and ivpb administration were not statistically different. Compare with ivpb, slow CRIS resulted in a more delayed t(max), but the C(max) values of slow CRIS and ivpb were not statistically different.

Original languageEnglish (US)
Pages (from-to)465-469
Number of pages5
JournalAnnals of Pharmacotherapy
Volume29
Issue number5
DOIs
StatePublished - Jan 1 1995
Externally publishedYes

Fingerprint

Tobramycin
Intravenous Infusions
Area Under Curve
Pharmacokinetics
Intravenous Administration
Volunteers
Half-Life
Healthy Volunteers
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Comparison of tobramycin pharmacokinetics after administration by CRIS and a traditional intravenous piggyback infusion. / Mauro, V. F.; Jacobs, L. R.; Mauro, L. S.; MacArthur, Rodger David; White, D. B.

In: Annals of Pharmacotherapy, Vol. 29, No. 5, 01.01.1995, p. 465-469.

Research output: Contribution to journalArticle

@article{308d535e99cd4b0297c9265b04b72f0c,
title = "Comparison of tobramycin pharmacokinetics after administration by CRIS and a traditional intravenous piggyback infusion",
abstract = "OBJECTIVE: To compare the administration pharmacokinetics of a 30-minute intravenous piggyback (ivpb) infusion of tobramycin with those of controlled- release infusion system (CRIS) using a 20-mL vial at rates of 60 and 120 mL/h. DESIGN: Randomized, controlled, crossover, prospective, open-label trial. SETTING: Medical college-affiliated hospital. PARTICIPANTS: Eight healthy volunteer men between the ages of 22 and 24 years weighing between 60 and 90 kg. INTERVENTIONS: Volunteers received, in random order, tobramycin sulfate 2 mg/kg iv on 3 occasions separated by 1 week. The drug was administered using a 50-mL ivpb infusion at 100 mL/h for 30 minutes, and with the CRIS using a 20-mL vial with flow rates of 60 mL/h for 1 hour (slow) and 120 mL/h for 1 hour (fast). MAIN OUTCOME MEASURES: Primary endpoint were area under the time-concentration curve (AUC), time to reach maximum concentration (t(max)), and maximum concentration (C(max)). Secondary endpoints were elimination rate constant (k(e)), clearance (Cl), and half-life (t( 1/2 )). RESULTS: Six volunteers successfully completed the trial. The t(max) values observed following fast CRIS and ivpb were 28 ± 8 and 32 ± 4 minutes, respectively, and not significantly different from each other. Both occurred significantly earlier than the t(max) associated with slow CRIS (44 ± 7 min), The C(max) values observed following ivpb (11.2 ± 1.5 mg/L) and slow CRIS (10.9 ± 0.9 mg/L) administration were not significantly different from each other, but both were significantly lower than that of fast CRIS (13.4 ± 1.5 mg/L). The AUCs of slow and fast CRIS were 29.8 ± 4.8 and 31.2 ± 3.8 mg/L · h, respectively, and were not significantly different from each other. The AUC of first CRIS was significantly greater than that observed with ivpb (27.4 ± 4.3 mg/L · h). No significant difference in k(e) (fast CRIS 0.32 ± 0.03 h -1 ; slow CRIS 0.33 ± 0.04 h -1 ; ivpb 0.34 ± 0.0 h - 1 ) was observed among any of the methods. CONCLUSIONS: CRIS administration of tobramycin resulted in higher AUCs than did ivpb administration. Compared with ivpb, fast CRIS resulted in a higher C(max), but the t(max) values of fast CRIS and ivpb administration were not statistically different. Compare with ivpb, slow CRIS resulted in a more delayed t(max), but the C(max) values of slow CRIS and ivpb were not statistically different.",
author = "Mauro, {V. F.} and Jacobs, {L. R.} and Mauro, {L. S.} and MacArthur, {Rodger David} and White, {D. B.}",
year = "1995",
month = "1",
day = "1",
doi = "10.1177/106002809502900502",
language = "English (US)",
volume = "29",
pages = "465--469",
journal = "Annals of Pharmacotherapy",
issn = "1060-0280",
publisher = "Harvey Whitney Books Company",
number = "5",

}

TY - JOUR

T1 - Comparison of tobramycin pharmacokinetics after administration by CRIS and a traditional intravenous piggyback infusion

AU - Mauro, V. F.

AU - Jacobs, L. R.

AU - Mauro, L. S.

AU - MacArthur, Rodger David

AU - White, D. B.

PY - 1995/1/1

Y1 - 1995/1/1

N2 - OBJECTIVE: To compare the administration pharmacokinetics of a 30-minute intravenous piggyback (ivpb) infusion of tobramycin with those of controlled- release infusion system (CRIS) using a 20-mL vial at rates of 60 and 120 mL/h. DESIGN: Randomized, controlled, crossover, prospective, open-label trial. SETTING: Medical college-affiliated hospital. PARTICIPANTS: Eight healthy volunteer men between the ages of 22 and 24 years weighing between 60 and 90 kg. INTERVENTIONS: Volunteers received, in random order, tobramycin sulfate 2 mg/kg iv on 3 occasions separated by 1 week. The drug was administered using a 50-mL ivpb infusion at 100 mL/h for 30 minutes, and with the CRIS using a 20-mL vial with flow rates of 60 mL/h for 1 hour (slow) and 120 mL/h for 1 hour (fast). MAIN OUTCOME MEASURES: Primary endpoint were area under the time-concentration curve (AUC), time to reach maximum concentration (t(max)), and maximum concentration (C(max)). Secondary endpoints were elimination rate constant (k(e)), clearance (Cl), and half-life (t( 1/2 )). RESULTS: Six volunteers successfully completed the trial. The t(max) values observed following fast CRIS and ivpb were 28 ± 8 and 32 ± 4 minutes, respectively, and not significantly different from each other. Both occurred significantly earlier than the t(max) associated with slow CRIS (44 ± 7 min), The C(max) values observed following ivpb (11.2 ± 1.5 mg/L) and slow CRIS (10.9 ± 0.9 mg/L) administration were not significantly different from each other, but both were significantly lower than that of fast CRIS (13.4 ± 1.5 mg/L). The AUCs of slow and fast CRIS were 29.8 ± 4.8 and 31.2 ± 3.8 mg/L · h, respectively, and were not significantly different from each other. The AUC of first CRIS was significantly greater than that observed with ivpb (27.4 ± 4.3 mg/L · h). No significant difference in k(e) (fast CRIS 0.32 ± 0.03 h -1 ; slow CRIS 0.33 ± 0.04 h -1 ; ivpb 0.34 ± 0.0 h - 1 ) was observed among any of the methods. CONCLUSIONS: CRIS administration of tobramycin resulted in higher AUCs than did ivpb administration. Compared with ivpb, fast CRIS resulted in a higher C(max), but the t(max) values of fast CRIS and ivpb administration were not statistically different. Compare with ivpb, slow CRIS resulted in a more delayed t(max), but the C(max) values of slow CRIS and ivpb were not statistically different.

AB - OBJECTIVE: To compare the administration pharmacokinetics of a 30-minute intravenous piggyback (ivpb) infusion of tobramycin with those of controlled- release infusion system (CRIS) using a 20-mL vial at rates of 60 and 120 mL/h. DESIGN: Randomized, controlled, crossover, prospective, open-label trial. SETTING: Medical college-affiliated hospital. PARTICIPANTS: Eight healthy volunteer men between the ages of 22 and 24 years weighing between 60 and 90 kg. INTERVENTIONS: Volunteers received, in random order, tobramycin sulfate 2 mg/kg iv on 3 occasions separated by 1 week. The drug was administered using a 50-mL ivpb infusion at 100 mL/h for 30 minutes, and with the CRIS using a 20-mL vial with flow rates of 60 mL/h for 1 hour (slow) and 120 mL/h for 1 hour (fast). MAIN OUTCOME MEASURES: Primary endpoint were area under the time-concentration curve (AUC), time to reach maximum concentration (t(max)), and maximum concentration (C(max)). Secondary endpoints were elimination rate constant (k(e)), clearance (Cl), and half-life (t( 1/2 )). RESULTS: Six volunteers successfully completed the trial. The t(max) values observed following fast CRIS and ivpb were 28 ± 8 and 32 ± 4 minutes, respectively, and not significantly different from each other. Both occurred significantly earlier than the t(max) associated with slow CRIS (44 ± 7 min), The C(max) values observed following ivpb (11.2 ± 1.5 mg/L) and slow CRIS (10.9 ± 0.9 mg/L) administration were not significantly different from each other, but both were significantly lower than that of fast CRIS (13.4 ± 1.5 mg/L). The AUCs of slow and fast CRIS were 29.8 ± 4.8 and 31.2 ± 3.8 mg/L · h, respectively, and were not significantly different from each other. The AUC of first CRIS was significantly greater than that observed with ivpb (27.4 ± 4.3 mg/L · h). No significant difference in k(e) (fast CRIS 0.32 ± 0.03 h -1 ; slow CRIS 0.33 ± 0.04 h -1 ; ivpb 0.34 ± 0.0 h - 1 ) was observed among any of the methods. CONCLUSIONS: CRIS administration of tobramycin resulted in higher AUCs than did ivpb administration. Compared with ivpb, fast CRIS resulted in a higher C(max), but the t(max) values of fast CRIS and ivpb administration were not statistically different. Compare with ivpb, slow CRIS resulted in a more delayed t(max), but the C(max) values of slow CRIS and ivpb were not statistically different.

UR - http://www.scopus.com/inward/record.url?scp=0028914843&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028914843&partnerID=8YFLogxK

U2 - 10.1177/106002809502900502

DO - 10.1177/106002809502900502

M3 - Article

C2 - 7655128

AN - SCOPUS:0028914843

VL - 29

SP - 465

EP - 469

JO - Annals of Pharmacotherapy

JF - Annals of Pharmacotherapy

SN - 1060-0280

IS - 5

ER -